FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer. PMID 41190384 · BJU Int · 2026-Jan The record is a secondary, post-hoc target trial emulation analysis of the ENZAMET trial data. While it uses data from a randomized trial and examines a time-to-event endpoint with drug interventions, it is not the original primary report of the Phase III ENZAMET trial itself, but a re-analysis within it. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial. PMID 41188524 · Nat Med · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial. PMID 41187971 · Diabetes Obes Metab · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1). PMID 41187967 · Diabetes Obes Metab · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment. PMID 41187013 · Obesity (Silver Spring) · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study. PMID 41182658 · BioDrugs · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Compound staphylococcal lysostaphin for oral mucositis prophylaxis in hematopoietic stem cell transplantation recipients: a non-inferiority randomized trial. PMID 41176574 · Br J Cancer · 2026-Jan The record does not meet key eligibility criteria: the trial phase is not confirmed as Phase III/IIIb or Phase II/III, the intervention is a non-drug supportive care mouthrinse, and the primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Serum Vitamin A Is Associated with Variations in the Relationship between Plasma B6 Vitamers and Cardiovascular Disease Risk. PMID 41176280 · J Nutr · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials. PMID 41175337 · Am J Clin Dermatol · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial. PMID 41173355 · Radiother Oncol · 2026-Jan The study is a human oncology (breast cancer) Phase III randomized trial with original results, but it evaluates a non-drug intervention (radiation fractionation schemes) and reports only technical quality assurance data, not the primary or key secondary time-to-event efficacy endpoints (e.g., OS, PFS, DFS). Therefore, it does not meet the criteria for a drug-containing intervention with a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. PMID 41173016 · Lancet Gastroenterol Hepatol · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial. PMID 41173015 · Lancet Gastroenterol Hepatol · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| POYANG: A phase III randomized clinical trial of faricimab for choroidal neovascularization secondary to pathologic myopia: study design and rationale. PMID 41152620 · Graefes Arch Clin Exp Ophthalmol · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Applying Evidence-Based Medicine Standards to Digital Tools. PMID 41151068 · Am J Health Promot · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study. PMID 41145670 · Leukemia · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Low Versus High Ligation of Inferior Mesenteric Artery in Rectal and Sigmoid Cancers: A Systematic Review, Meta-analysis, and Trial Sequential Analysis of Randomized Controlled Trials. PMID 41139188 · Ann Surg Oncol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC). PMID 41138857 · Radiother Oncol · 2026-Jan The study is a randomized, placebo-controlled, multicenter trial in human oncology patients with a drug intervention (nimorazole) and reports time-to-event efficacy outcomes (including HR). However, the abstract and metadata do not explicitly state the trial phase (e.g., Phase III, Phase II/III). Without explicit phase information, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The results of randomized controlled trial comparing effectiveness of transanal endoscopic microsurgery versus endoscopic submucosal dissection. PMID 41136652 · Surg Endosc · 2026-Jan Excluded because it is not a drug intervention trial and the endpoints are not the required time-to-event efficacy endpoints for malignant neoplasms. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Topical lidocaine or not for laser follicle ablation in pilonidal disease: A prospective, randomized, double-blinded trial. PMID 41135869 · J Pediatr Surg · 2026-Jan 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial. PMID 41128833 · CNS Drugs · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of baseline humoral immunity on treatment outcomes with molnupiravir in the MOVe-OUT randomized, controlled trial. PMID 41125063 · Virology · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. PMID 41120017 · Ann Oncol · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials. PMID 41118053 · Am J Clin Dermatol · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies. PMID 41115533 · J Allergy Clin Immunol · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO. PMID 41115464 · Ann Oncol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. PMID 41110694 · Ann Oncol · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease. PMID 41109840 · J Prev Alzheimers Dis · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Oral gepotidacin for the treatment of uncomplicated urinary tract infection in Japanese female patients: a randomized, active reference, double-blind, double-dummy, Phase 3 trial (EAGLE-J). PMID 41109603 · J Infect Chemother · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials. PMID 41108138 · Genet Med · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial. PMID 41107178 · Eur Urol · 2026-Jan The record describes a randomized screening trial comparing diagnostic tests (PSA vs Stockholm3) for prostate cancer, not a therapeutic trial with a drug-containing intervention in a Phase III/IIIb or Phase II/III setting. Although it reports time-to-event outcomes (biochemical recurrence) and is an original result, the absence of a drug intervention and definitive Phase III therapeutic evidence makes it ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study. PMID 41102077 · Allergol Int · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. PMID 41090431 · Diabetes Obes Metab · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216). PMID 41087530 · Br J Cancer · 2026-Jan The study is a Phase III, prospective, non-randomized trial. The inclusion criteria require randomized trials. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Methodological and reporting rigor in noninferiority and equivalence trials for multimodality cancer treatment: lessons from breast cancer radiotherapy. PMID 41077326 · J Clin Epidemiol · 2026-Jan The record is a methodological review analyzing multiple non-inferiority/equivalence trials in breast cancer radiotherapy. It is not an original report of a single randomized trial with drug intervention and time-to-event efficacy endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses. PMID 41072729 · Ann Allergy Asthma Immunol · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tranexamic acid to prevent bleeding in patients with hematologic malignancies and hypoproliferative thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. PMID 41067389 · J Thromb Haemost · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| ASO Visual Abstract: Synergistic Effects of Psychological Resilience Training and Nutritional Support on Postoperative Recovery, Nutritional Reconstitution, Sleep Quality, and Long-term Survival in Gastric Cancer-A Randomized Controlled Trial. PMID 41057749 · Ann Surg Oncol · 2026-Jan The record lacks sufficient metadata to establish key criteria: no human subjects confirmation, no phase (Phase III/IIIb or II/III) confirmation, no drug-containing intervention (interventions are psychological/nutritional), no primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc., Kaplan-Meier, or HR) mentioned, and no confirmation of a primary result report. The title suggests a randomized trial in gastric cancer (oncology), but the core eligibility criteria are not met. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [Bacterial decolonization with mupirocin ointment reduces severe radiation-induced oral mucositis in nasopharyngeal carcinoma: results of a randomized phase 3 trial]. PMID 41051489 · Strahlenther Onkol · 2026-Jan The record describes a randomized phase 3 trial in nasopharyngeal carcinoma (oncology) with a drug-containing intervention (mupirocin ointment), but the abstract provides no information on time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR data. The primary endpoint appears to be severe radiation-induced oral mucositis, which is a safety/toxicity endpoint, not a time-to-event efficacy endpoint. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort focused on time-to-event efficacy. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Poly(ADP-ribose) Polymerase Inhibitors According to Clinical Risk in Newly Diagnosed, Advanced Ovarian Cancer: A Meta-analysis of Phase III Clinical Trials. PMID 41042468 · Ann Surg Oncol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial. PMID 41033921 · Eur Urol · 2026-Jan The record describes a Phase 2 randomized trial comparing radiotherapy regimens, not a drug-containing intervention. While ADT was allowed, it was not the experimental intervention being tested. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Does Messaging for Reducing Breast Cancer Overscreening in Older Women Have Differential Responses among Medical Minimizers and Maximizers? PMID 41020449 · Med Decis Making · 2026-Jan The study is a randomized controlled survey experiment evaluating a messaging intervention to reduce breast cancer overscreening. It is a non-drug-only intervention (messaging strategy), does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.), and is not a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention. It is therefore ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials. PMID 41006920 · Am J Clin Dermatol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease. PMID 40992967 · Ann Rheum Dis · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial. PMID 40976531 · J Am Acad Dermatol · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of a China-developed live attenuated herpes zoster vaccine in Chinese healthy adults aged 40 years and older: a multicentre, randomized, double-blind, placebo-controlled, phase 3 clinical trial. PMID 40962113 · Clin Microbiol Infect · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer. PMID 40956664 · J Urol · 2026-Jan The record describes a Phase II/III trial of a drug-containing regimen with primary time-to-event efficacy endpoints (DFS, PFS). However, the study appears to be a single-arm trial (open-label, no control group mentioned), and there is no explicit evidence of randomization. Therefore, it does not meet the requirement for a randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of immune checkpoint inhibitors for locoregionally advanced, recurrent and metastatic nasopharyngeal carcinoma: a systematic review of phase III randomised controlled trials. PMID 40952475 · Naunyn Schmiedebergs Arch Pharmacol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial. PMID 40945526 · Lancet Infect Dis · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Preclinical Ischemic Stroke Multicenter Trials (PRISM) Collective Statement: Opportunities, Challenges, and Recommendations for a New Era. PMID 40931817 · Stroke · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| [18F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson's disease: dosimetry and pharmacokinetics. PMID 40924149 · Eur J Nucl Med Mol Imaging · 2026-Jan The study is a Phase II/III imaging and dosimetry trial in Parkinson's disease (a non-oncology indication), not a malignancy. It is a human, original result report but lacks a drug intervention, is not randomized, and has no time-to-event efficacy endpoint. It does not meet any of the core eligibility criteria for the oncology Kaplan-Meier cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |